![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS-
650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection
|
|
|
Reported by Jules Levin
AASLD Nov 3 2009, Boston, MA
C. Pasquinelli, T. Eley, C. Villegas, K. Sandy, E. Mathias,
P. Wendelburg, S. Liao, F. McPhee, P. Scola, L. Sun, T Marbury,
E Lawitz, P. Goldwater, M. Rodriguez-Torres, M. DeMicco, M. Ababa,
D. Wright, M. Charlton, W. Kraft, J-C, Lopez-Talavera, DM. Grasela
![add.gif](../images/110609/110609-7/add.gif)
![image002.gif](../images/110409/110409-4/image002.gif)
![image004.gif](../images/110409/110409-4/image004.gif)
![image006.gif](../images/110409/110409-4/image006.gif)
![image008.gif](../images/110409/110409-4/image008.gif)
![image010.gif](../images/110409/110409-4/image010.gif)
![image012.gif](../images/110409/110409-4/image012.gif)
![image014.gif](../images/110409/110409-4/image014.gif)
![image016.gif](../images/110409/110409-4/image016.gif)
![image018.gif](../images/110409/110409-4/image018.gif)
![image020.gif](../images/110409/110409-4/image020.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|